The analyst pointed out Ultralife's strategic moves post-COVID, which have increased scale and capacity. The addition of Electrochem's assets has already started to improve margins and is anticipated to further enhance profitability as volumes return. In summary, Sullivan expects Ultralife's medical wearable technology to secure more orders this year, the Electrochem integration to conclude soon, and the server case venture to keep progressing. In other recent news, Ultralife Corporation reported its Q1 2025 earnings, showing a revenue of $50.7 million, which surpassed the forecast of $48 million. Despite this revenue beat, the company's earnings per share (EPS) fell short, coming in at $0.11 compared to the expected $0.14. The strong revenue performance was driven by a 53.6% increase in government defense sales, though the company faced challenges in its Communications Systems (NASDAQ: SUNE ) division, where revenue declined significantly.